Preparation and Evaluation of a Sustained Release Formulation of Metoclopramide Hydrochloride HPMC Tablets

The objective of the present study was to develop “once daily” sustained release tablets of metoclopramide hydrochloride by direct compression using hydroxypropyl methylcellulose (HPMC). No significant changes in terms of peak shifting, appearance or disappearance of peaks were noted with pure drug, polymers and mixtures. The developed sustained release and marketed immediate release of metoclopramide hydrochloride were appraised for physico-chemical parameters such as appearance, weight variation, thickness, hardness, friability and in vitro release study. Developed sustained release tablets of metoclopramide hydrochloride with respect to its physicochemical parameters and drug content are stable at long term storage conditions at 25 o C and 60% RH, and accelerated conditions at 40 o C and 75% RH for a period of six months. The in vitro drug release of Metoclopramide hydrochloride sustained release was compared with the marketed immediate release. The sustained release tablets of metoclopramide hydrochloride were well absorbed and the extent of absorption was higher than that of the marketed tablet. The Cmax and tmax data showed higher for immediate release compared to sustain release formulation. Developed Metoclopramide hydrochloride sustained release tablets demonstrated higher AUC, half-life and lower elimination rate constant values is indicative, that drug leftover in the body for extended period of time and showed signs of prolonged effect. The sustained and efficient drug delivery system developed in the present study will maintain plasma Metoclopramide hydrochloride levels better, which resolve the drawbacks related with the conventional therapy.

PDF

___

1. The United States Pharmacopeia, 24th Ed. The United States Pharmacopoeial Convention Inc, Rockville, MD, metoclopramide hydrochloride monograph. 2006.

2. Rx List Drug information.

3. Heng PW, Chah LW. Parikh DM. Drug substance and excipient characterization. In: Handbook of Pharmaceutical Granulation Technology. Decker, New York. 1997, pp 52–55.

4. Hamed E, Sakr A. Application of multiple response optimization technique to extended release formulations design. J Control Release 2001; 73: 329-38.

5. Sayed IAR, Gamal MM, Mahmoud BE. Preparation and comparative evaluation of sustained release metoclopramide hydrochloride matrix tablets. Saudi Pharm J 2009; 17: 283-8.

6. Hasan EI, Amro BI, Arafat T, Badwan AA. Assessment of controlled release of hydrophilic matrix formulation for metoclopramide hydrochloric acid. Eur J Pharm Biopharm 2003; 55: 339–44.

7. Bhavesh S, Surendra G, Sanjay S. Formulation and evaluation of bi-layer tablet of metoclopramide hydrochloride and ibuprofen. AAPS PharmSciTech 2008; 9: 818–27.

8. Gattani SG, Khabiya SS, Amrutkar JR, Kushare SS. Formulation and evaluation of bilayer tablets of metoclopramide hydrochloride and diclofenac sodium. PDA J Pharm Sci Technol 2012; 66:151-60.

9. Leon L, Herbert LA. The theory and practice of industrial pharmacy. Special Indian edition. 2009: 293-373.

10. Pharmacopoeia of India. New Delhi: Ministry of Health and Family Welfare, Government of India, Controller of Publications. 1996.

11. US FDA Guidance for industry. Dissolution testing of immediate release solid oral dosage forms. US FDA Center for drug evaluation and research, Rockville, MD. 1997

12. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 1988; 29: 1035-41.

13. Khan MA, Mehta RK. Studies on Multimedia dissolution profile of zolpidem tartrate sustained release matrix tablets. Res J Pharm Biol Chem Sci 2012; 3: 174-7.

14. Khan MA. The influence of pH on drug release from zidovudine matrices containing different grades of hydroxypropyl methyl cellulose. AJPST 2014; 4: 1-3.

15. Khan MA, Maheshwari RK, Studies of relationship between swelling and drug release in the sustained release hydrophilic matrices containing different grades of hdroxypropylmethyl cellulose. Res J Pharm Biol Chem 2011; 2: 970.

16. ICH Guidelines. Stability testing of new drug substances and products, Q1A (R2) Step 4 version. 2003.

17. Jaswanth KI, Rajasekhar D, Ramesh M, Venkateswarlu P. Sensitive and selective liquid chromatography–tandem mass spectrometry method for the determination of metoclopramide in human plasma: application to a bioequivalence study. Biomed Chromatogr 2010; 24: 1006–14.

18. Yan M, Li HD, Chen BM, Liu XL, Zhu YG. Determination of metoclopramide in human plasma by LC-ESI-MS and its application to bioequivalance studies. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 883-7.

19. Beckett AH, Behrendt WA, Hadzija BW. Bioavailability of controlled-release metoclopramide single dose study. Arzneimettelforsch 1987; 37: 221–4.